Ertugliflozin
- Generic Name
- Ertugliflozin
- Brand Names
- Segluromet, Steglatro, Steglujan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25ClO7
- CAS Number
- 1210344-57-2
- Unique Ingredient Identifier
- 6C282481IP
- Background
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Ertugliflozin was first approved by the FDA in December 2017. It was also approved by the European Commission in March 2018.
- Indication
Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM). It is also available in combination with either metformin or sitagliptin.
Ertugliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
- Conditions
- CongestionHeart Failure With Reduced Ejection Fraction
- Interventions
- Drug: ErtugliflozinDrug: Placebo
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 28
- Registration Number
- NCT05152940
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)
- Conditions
- Heart Failure With Nonischemic Cardiomyopathy
- Interventions
- Drug: ErtugliflozinDrug: Placebo
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 52
- Registration Number
- NCT04490681
- Locations
- 🇰🇷
Severance Hospiatal, Seoul, Korea, Republic of
Ertugliflozin in Chronic Heart Failure
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 60
- Registration Number
- NCT04438213
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Ertugliflozin for Functional Mitral Regurgitation
- Conditions
- Left Ventricular Systolic DysfunctionMitral Valve Insufficiency
- Interventions
- Drug: PlaceboDrug: Ertugliflozin
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 128
- Registration Number
- NCT04231331
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
- Conditions
- Cardiovascular DiseasesAtherosclerosisType 2 DiabetesInsulin Resistance
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 61
- Registration Number
- NCT04167761
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Effect of Ertugliflozin on Cardiac Function in Diabetes
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Soo Lim
- Target Recruit Count
- 102
- Registration Number
- NCT03717194
- Locations
- 🇰🇷
Seoul National University Bundang Hospita;, Seongnam-si, Gyeonggi-do, Korea, Republic of
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
- Conditions
- HypertensionDiabetes Mellitus, Type 2
- Interventions
- Drug: Hydrochlorothiazide 12.5mgDrug: ErtugliflozinDevice: MicroneurographyOther: SKNA recordingsOther: Static HandgripOther: Post-handgrip forearm vascular occlusionOther: Testing of the Arterial Baroreflex Function
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Cedars-Sinai Medical Center
- Registration Number
- NCT03640221
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
- Conditions
- Type 2 Diabetes MellitusHeart Failure
- Interventions
- Drug: ErtugliflozinDrug: Placebo
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 34
- Registration Number
- NCT03416270
- Locations
- 🇳🇱
Vanderbilt University Medical Centre, Amsterdam, De Boelelaan, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 291
- Registration Number
- NCT02226003
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8246
- Registration Number
- NCT01986881
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.